Luteinising hormone releasing hormone analogues (LHRHA) in prostate cancer: Evidence Based or Class Effect?

摘要

Prostate cancer is the most common cancer for men in the UK, with almost 35,000 men diagnosed each year and some 10,000 men a year dying from the condition. The management of men with prostate cancer is an increasingly complex process with a variety of available treatments, factors influencing treatment choice and involvement of a cross-section of disciplines from both primary and secondary care.